Association of body composition and systemic inflammation for patients with locally advanced cervical cancer following concurrent chemoradiotherapy

被引:0
|
作者
Li, Juan [1 ]
Niu, Cuili [1 ]
Zhang, Ling [1 ]
Mu, Yanmin [1 ]
Gui, Xiuyin [1 ]
机构
[1] Xingtai Third Hosp, Clin Gynecol, Xingtai, Peoples R China
来源
关键词
Cervical cancer; concurrent chemoradiotherapy; systemic inflammation; body composition; prognosis; VISCERAL FAT PERCENTAGE; PROGNOSTIC VALUE; SARCOPENIA; OBESITY; PREDICTION; MARKERS; CELLS;
D O I
10.4274/dir.2024.242751
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE Systemic inflammation and body composition are associated with survival outcomes of cancer patients. This study aimed to examine the combined prognostic value of systemic inflammatory markers and body composition parameters in patients with locally advanced cervical cancer (LACC). METHODS Patients who underwent concurrent chemoradiotherapy (CCRT) for LACC at a tertiary referral teaching hospital between January 2010 and January 2018 were enrolled. A predictive model was established based on systemic immune-inflammation index (SII) and computer tomography-derived visceral fat-to-muscle ratio (vFMR). Overall survival (OS) and progression-free survival (PFS) were assessed using the Kaplan-Meier method and Cox regression models. The model performance was assessed using discrimination, calibration, and clinical usefulness. RESULTS In total, 212 patients were enrolled. The SII and vFMR were closely related, and both independently predicted survival (P < 0.05). A predictive model was established based on the above biomarkers and included three subgroups: high-risk [both high SII (>828) and high vFMR (>1.1)], middle-risk (either high SII or high vFMR), and low-risk (neither high SII nor high vFMR). The 3-year OS (PFS) rates for low-, middle-, and high-risk patients were 90.5% (86.0%), 73.9% (58.4%), and 46.8% (36.1%), respectively (P < 0.05). This model demonstrated satisfactory predictive accuracy (area under the curve values for predicting 3-year OS and PFS were 0.704 and 0.718, respectively), good fit (Hosmer-Lemeshow tests: P > 0.05), and clinical usefulness. CONCLUSION Systemic inflammatory markers combined with body composition parameters could independently predict the prognosis of patients with LACC, highlighting the utilization of commonly collected indicators in decision-making processes.
引用
收藏
页码:279 / 290
页数:12
相关论文
共 50 条
  • [31] Analysis of Treatment Outcomes and Prognosis After Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
    Peng, Qing-he
    Chen, Kai
    Li, Jun-yun
    Chen, Li
    Ye, Wei-jun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [32] CONCURRENT CHEMORADIOTHERAPY WITH HIGH-DOSE-RATE BRACHYTHERAPY FOR LOCALLY ADVANCED CERVICAL CANCER
    Kim, Y. S.
    Kim, J. H.
    Lee, S. W.
    Yoon, S. M.
    Ahn, S. D.
    Choi, E. K.
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S310 - S310
  • [33] Phase II study of tislelizumab combined with concurrent chemoradiotherapy for locally advanced cervical cancer
    Ma, Shanshan
    Zhang, Yong
    Wu, Fang
    Jiang, Li
    Zhang, Tingting
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Pelvic node control in locally advanced uterine cervical cancer treated with concurrent chemoradiotherapy
    Toita, T.
    Tamaki, W.
    Nagai, Y.
    Ogawa, K.
    Gibo, S.
    Kakinohana, Y.
    Hirakawa, M.
    Kamiyama, K.
    Aoki, Y.
    Murayama, S.
    EJC SUPPLEMENTS, 2007, 5 (04): : 321 - 322
  • [35] SURGERY AFTER CONCURRENT CHEMORADIOTHERAPY AND BRACHYTHERAPY IN LOCALLY ADVANCED CERVICAL CANCER: MORBIDITY AND OUTCOME
    Aloui, Marwa
    Zemni, Ines
    Sakhri, Saida
    Jaouadi, Souha
    Chargui, Riadh
    Ben Dhied, Tarek
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A100 - A100
  • [36] Research on the efficacy of cisplatin and nimotuzumab combined with concurrent chemoradiotherapy on locally advanced cervical cancer
    Cao, Ye
    Deng, Li
    Lian, Shixian
    Jiang, Ying
    JOURNAL OF BUON, 2019, 24 (05): : 2013 - 2019
  • [37] Comparison of the curative effect and safety of consolidation chemotherapy after concurrent chemoradiotherapy with concurrent chemoradiotherapy alone for locally advanced cervical cancer
    Tu, Kaijia
    Chen, Cai
    Cheng, Xiaoxiao
    Li, Longyu
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (04) : 558 - 563
  • [38] Surgical Efficacy and Safety of Patients with Locally Advanced Gastric Cancer following Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy
    Li, Ching-Chun
    Yeh, Yung-Sung
    Chen, Yen-Cheng
    Su, Wei-Chih
    Chang, Tsung-Kun
    Tsai, Hsiang-Lin
    Huang, Ching-Wen
    Ma, Cheng-Jen
    Yin, Tzu-Chieh
    Chen, Po-Jung
    Wang, Jaw-Yuan
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [39] Optimal cisplatin cycles in locally advanced cervical carcinoma patients treated with concurrent chemoradiotherapy
    Zeng, Zheng
    Wang, Weiping
    Liu, Xiaoliang
    Wang, Guangyu
    Ren, Kang
    Zhang, Fuquan
    Hu, Ke
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (10): : 2892 - 2900
  • [40] Optimal Cisplatin Cycles in Locally Advanced Cervical Carcinoma Patients Treated with Concurrent Chemoradiotherapy
    Zeng, Z.
    Zhang, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E559 - E559